Literature DB >> 30004058

Bacteriological profile of ventilator-associated pneumonia in a tertiary care hospital.

Somi Patro1, Gitanjali Sarangi1, Padma Das2, Ashoka Mahapatra3, Dharitri Mohapatra1, Bimoch Projna Paty1, Nirupama Chayani1.   

Abstract

BACKGROUND: Ventilator-associated pneumonia (VAP) is the most frequent intensive care unit (ICU)-acquired infection. The etiology of VAP and their antimicrobial susceptibility pattern varies with different patient populations and types of ICUs.
MATERIALS AND METHODS: An observational cross-sectional study was performed over a period of 2 years in a tertiary care hospital to determine the various etiological agents causing VAP and to detect the presence of multidrug-resistant (MDR) pathogens in these VAP patients. Combination disk method, Modified Hodge test, ethylenediaminetetraacetic acid disk synergy test, and AmpC disk test were performed for the detection of extended-spectrum beta-lactamase (ESBL), carbapenemases, metallo-beta-lactamases (MBL), and AmpC beta-lactamases, respectively.
RESULTS: The prevalence of VAP was 35%. Enterobacteriaceae (66.66%) and Staphylococcus aureus (20%) were common in early-onset VAP, while nonfermenters (50%) and Enterobacteriaceae (40.61%) were predominant from late-onset VAP. Nearly 60.87% of the bacterial pathogens were MDR. ESBL was produced by 21.74% of Enterobacteriaceae. AmpC β-lactamase was positive in 35.29% nonfermenters and 26.08% Enterobacteriaceae. MBL was positive in 17.64% nonfermenters and 17.39% Enterobacteriaceae. Among the S. aureus isolates, 75% were cefoxitin resistant. Prior antibiotic therapy (P = 0.001) and hospitalization of 5 days or more (P = 0.001) were independent risk factors for VAP by MDR pathogens. polymyxin B, tigecycline, and vancomycin were the most sensitive drugs for Gram-negative and positive isolates respectively from VAP. STATISTICAL ANALYSIS: SPSS for Windows Version SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and Chi-square with Yates correction.
CONCLUSION: Late-onset VAP is increasingly associated with MDR pathogens. Treatment with polymyxin B, tigecycline, and vancomycin should be kept as last-line reserve drugs against most of the MDR pathogens.

Entities:  

Keywords:  Multidrug resistant; risk factors; ventilator-associated pneumonia

Mesh:

Substances:

Year:  2018        PMID: 30004058     DOI: 10.4103/IJPM.IJPM_487_16

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  6 in total

1.  Prevalence of multidrug-resistant strains in device associated nosocomial infection and their in vitro killing by nanocomposites.

Authors:  Shahbaz Aman; Divya Mittal; Shalini Shriwastav; Hardeep Singh Tuli; Shubham Chauhan; Pardeep Singh; Sheetal Sharma; Reena V Saini; Narinder Kaur; Adesh K Saini
Journal:  Ann Med Surg (Lond)       Date:  2022-05-03

2.  Trimetoprim-sulfametoxazole in ventilator-associated pneumonia: a cohort study.

Authors:  Alessio Strazzulla; Maria Concetta Postorino; Anastasia Purcarea; Catherine Chakvetadze; Astrid de Farcy de Pontfarcy; Gianpiero Tebano; Aurelia Pitsch; Lyvan Vong; Sebastien Jochmans; Christophe Vinsonneau; Mehran Monchi; Sylvain Diamantis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-01       Impact factor: 3.267

3.  Antimicrobial Resistance Patterns in Clinically Significant Isolates from Medical Wards of a Tertiary Care Hospital in North India.

Authors:  Venkatesh Sudharsan Vaithiyam; Neha Rastogi; Piyush Ranjan; Niranjan Mahishi; Arti Kapil; Sada Nand Dwivedi; Manish Soneja; Naveet Wig; Ashutosh Biswas
Journal:  J Lab Physicians       Date:  2020-11-23

4.  Emergence of blaNDM-1 and blaVIM producing Gram-negative bacilli in ventilator-associated pneumonia at AMR Surveillance Regional Reference Laboratory in India.

Authors:  Mithlesh Kumari; Sheetal Verma; Vimala Venkatesh; Prashant Gupta; Piyush Tripathi; Avinash Agarwal; Suhail Sarwar Siddiqui; Zia Arshad; Ved Prakash
Journal:  PLoS One       Date:  2021-09-08       Impact factor: 3.240

5.  Risk Factors and Protective Factors against Ventilator-Associated Pneumonia-A Single-Center Mixed Prospective and Retrospective Cohort Study.

Authors:  Jarosław Pawlik; Lucyna Tomaszek; Henryk Mazurek; Wioletta Mędrzycka-Dąbrowska
Journal:  J Pers Med       Date:  2022-04-08

6.  Carbapenem-Resistant Klebsiella pneumoniae Among Patients with Ventilator-Associated Pneumonia: Evaluation of Antibiotic Combinations and Susceptibility to New Antibiotics.

Authors:  Raghdaa A Ramadan; Aya M Bedawy; Essamedin M Negm; Tarek H Hassan; Dalia A Ibrahim; Somia M ElSheikh; Rania M Amer
Journal:  Infect Drug Resist       Date:  2022-07-06       Impact factor: 4.177

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.